Journal of Substance Abuse Treatment
Volume 39, Issue 4 , Pages 307-317 , December 2010

A national study of a telephone support service for patients receiving office-based buprenorphine medication-assisted treatment: Study feasibility and sample description

  • Charles Ruetsch, Ph.D.

      Affiliations

    • Health Analytics, LLC, Columbia, MD 21045, USA
    • Corresponding Author InformationCorresponding author. Health Analytics, 9200 Rumsey Road, Suite 215, Columbia, MD 21045. Tel.: +1 410 997 3314; fax: +1 410 997 4545.
    • ,
  • John Cacciola, Ph.D.

      Affiliations

    • Treatment Research Institute, Philadelphia, PA 1906, USA
    • ,
  • Joseph Tkacz, M.S.

      Affiliations

    • Health Analytics, LLC, Columbia, MD 21045, USA

Received 2 October 2009 ,Revised 9 July 2010 ,Accepted 12 July 2010.

References 

  1. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment. 2005;28:321–329
  2. Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction. 2009;104:982–992
  3. Bell J, Burrell T, Indig D, Gilmour S. Cycling in and out of treatment; Participation in methadone treatment in NSW, 1990–2002. Drug & Alcohol Dependence. 2006;81:55–61
  4. Braithwaite D, Emery J, de Lusignan S, Sutton S. Using the Internet to conduct surveys of health professionals: A valid alternative?. Family Practice. 2003;20:545–551
  5. Cacciola JS, Alterman AI, Lynch KG, Martin JM, Beauchamp ML, McLellan AT. Initial reliability and validity studies of the Revised Treatment Services Review (TSR-6). Drug & Alcohol Dependence. 2008;92:37–47
  6. Cacciola JS, Camilleri AC, Carise D, et al. Extending residential care through telephone counseling: Initial results from the Betty Ford Center focused continuing care protocol. Addictive Behaviors. 2008;33:1208–1216
  7. Carise D, McLellan AT, Gifford LS, Kleber HD. Developing a national addiction treatment information system. An introduction to the Drug Evaluation Network System. Journal of Substance Abuse Treatment. 1999;17:67–77
  8. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: The international experience. Clinical Infectious Diseases. 2006;43(Suppl 4):S197–S215
  9. Center for Substance Abuse Treatment . Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004;
  10. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technology Assessment (Winchester, England). 2007;11:1–171
  11. Cramer J, Rosenheck R, Kirk G, et al. Medication compliance feedback and monitoring in a clinical trial: Predictors and outcomes. Value Health. 2003;6:566–572
  12. Darke S. Self-report among injecting drug users: A review. Drug and Alcohol Dependence. 1998;51:253–263
  13. Dolor RJ, Yancy WS, Owen WF, et al. Hypertension improvement project (HIP): Study protocol and implementation challenges. Trials [Electronic Resource]. 2009;10:13
  14. East L, Jackson D, O'Brien L, Peters K. The benefits of computer-mediated communication in nursing research. Contemporary Nurse. 2008;30:83–88
  15. Eisen A, Kushner H, McLeod M, Queen E, Gordon J, Ford JL. An integrated approach to addressing addiction and depression in college students. Journal of American College Health. 2009;57:455–456
  16. Elder JP, Ayala GX, Harris S. Theories and intervention approaches to health-behavior change in primary care. American Journal of Preventive Medicine. 1999;17:275–284
  17. Fiellin DA, et al. Long-term treatment with buprenorphine/naloxone in primary care: Results at 2–5 years. Am J Addict. 2008;17:116–120
  18. Geurts M, Blowers L. Global subject recruitment. Applied Clinical Trials. 2009;18:91–93Retrieved from http://search.ebscohost.com.proxy-hs.researchport.umd.edu/login.aspx?direct=true&db=aph&AN=37179067&site=ehost-live
  19. Hubbard RL, Leimberger JD, et al. Telephone Enhancement of Long-term Engagement (TELE) in continuing care for substance abuse treatment: A NIDA clinical trials network (CTN) study. American Journal on Addictions. 2007;16:495–502
  20. Improving outcomes for opioid-addicted youth . Harvard Mental Health Letter. 2009;25:7
  21. Kastelic A, Pont J, Heino S. Opioid Substitution Treatment in Custodial Settings. World Health Organization; United Nations Office on Drugs and Crime; 2008;
  22. Katz N, Fernandez K, Chang A, Benoit C, Butler SF. Internet-based survey of nonmedical prescription opioid use in the United States. Clinical Journal of Pain. 2008;24:528–535
  23. Kaur AD, McQueen A, Jan S. Opioid drug utilization and cost outcomes associated with the use of buprenorphine–naloxone in patients with a history of prescription opioid use. Journal of Managed Care Pharmacy. 2008;14:186–194
  24. Magura S, et al. Outcomes of buprenorphine maintenance in office-based practice. Journal of Addictive Diseases. 2007;26:13–23
  25. Magura S, Lee JD, Hershberger J, Joseph H, Marsch L, Shropshire C, et al. Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial. Drug & Alcohol Dependence. 2009;99:222–230
  26. McKay JR, Lynch KG, Shepard DS, Pettinati HM. The effectiveness of telephone-based continuing care for alcohol and cocaine dependence: 24-Month outcomes. Archives of General Psychiatry. 2005;62:199–207
  27. McLellan AT, Arndt IO, et al. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269:1953–1959
  28. McLellan AT, Cacciola JC, et al. The Addiction Severity Index at 25: Origins, contributions and transitions. American Journal on Addictions. 2006;15:113–124
  29. McLellan AT, Hagan TA, Levine M, et al. Supplemental social services improve outcomes in public addiction treatment. Addiction. 1998;93:1489–1499
  30. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment. 1992;9:199–213
  31. Morin K, Rakatansky H, Riddick FA, Morse LJ, O'Bannon JM, Goldrich MS, et al. Managing conflicts of interest in the conduct of clinical trials. JAMA. 2002;287:78–84
  32. Netherland J, Botsko M, Egan JE, Saxon AJ, Cunningham CO, Finkelstein R, et al. Factors affecting willingness to provide buprenorphine treatment. Journal of Substance Abuse Treatment. 2009;36:244–251
  33. Ridge G, Gossop M, Lintzeris N, Witton J, Strang J. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. Journal of Substance Abuse Treatment. 2009;37:95–100
  34. Schottenfeld RS, Chawarski MC, Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: A randomized, double-blind, placebo-controlled trial. Lancet. 2008;371:2192–2200
  35. Scott CK, Dennis ML. Results from two randomized clinical trials evaluating the impact of quarterly recovery management checkups with adult chronic substance users. Addiction. 2009;104:959–971
  36. Shimm DS, Spece RG. Industry reimbursement for entering patients into clinical trials: Legal and ethical issues. Annals of Internal Medicine. 1991;115:148–151
  37. Substance Abuse and Mental Health Services Administration, Office of Applied Studies . Treatment episode data set (TEDS) highlights—2007 national admission to substance abuse treatment services No. OAS Seris #S-45, HHS Publication No.(SMA) 09-4360). Rockville, MD: US Department of Health and Human Services; 2009;
  38. United States. Department of Health and Human Services. - Inspections, Compliance, Enforcement, and Criminal Investigations. U.S Food and Drug Administration, 2009. Web. <http://www.fda.gov/ICECI/EnforcementActions/BioresearchMonitoring/ucm133927.htm>.
  39. Zanis DA, McLellan AT, Corse S. Is the Addiction Severity Index a reliable and valid assessment instrument among clients with severe and persistent mental illness and substance abuse disorders?. Community Mental Health Journal. 1997;33:213–227

PII: S0740-5472(10)00155-8

doi: 10.1016/j.jsat.2010.07.003

Journal of Substance Abuse Treatment
Volume 39, Issue 4 , Pages 307-317 , December 2010

Article Tools

* Image Usage & Resolution